The utility of MYC and FLT4 in the diagnosis and treatment of postradiation atypical vascular lesion and angiosarcoma of the breast

Human Pathology

Volumn 46, Issue 6, 2015, Pages 868-875

  Cornejo, Kristine M ^a   Deng, April ^a   Wu, Hong ^b   Cosar, Ediz F ^a   Khan, Ashraf ^a   St Cyr, Maryann ^a   Tomaszewicz, Keith ^a   Dresser, Karen ^a   O'Donnell, Patrick ^a   Hutchinson, Lloyd ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^b FOX CHASE CANCER CENTER   (United States)

Author keywords

Angiosarcoma; Atypical vascular lesion; FISH; FLT4; Immunohistochemistry; MYC; Post radiation

Indexed keywords

MYC PROTEIN; VASCULOTROPIN RECEPTOR 3; MYC PROTEIN, HUMAN; VEGFR3 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; ATYPICAL VASCULAR NEOPLASM; BREAST ANGIOSARCOMA; BREAST CANCER; BREAST SARCOMA; BREAST TUMOR; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENE AMPLIFICATION; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; ONCOGENE MYC; PAPULE; RADIATION INJURY; TUMOR BIOPSY; VASCULAR TUMOR; VERY ELDERLY; BREAST; BREAST NEOPLASMS; HEMANGIOSARCOMA; METABOLISM; PATHOLOGY; PROCEDURES; RADIATION INDUCED NEOPLASM; VASCULAR DISEASES;

ADULT; AGED; BREAST; BREAST NEOPLASMS; FEMALE; HEMANGIOSARCOMA; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; NEOPLASMS, RADIATION-INDUCED; PROTO-ONCOGENE PROTEINS C-MYC; VASCULAR DISEASES; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3;

EID: 84937965469     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2015.02.014     Document Type: Article

References (32)

1. C. Diaz-Cascajo, S. Borghi, W. Weyers, H. Retzlaff, L. Requena, and D. Metze Benign lymphangiomatous papules of the skin following radiotherapy: a report of five new cases and review of the literature Histopathology 35 1999 319 327
2. L. Requena, H. Kutzner, T. Mentzel, R. Duran, and J.L. Rodriguez-Peralto Benign vascular proliferations in irradiated skin Am J Surg Pathol 26 2002 328 337
3. I.W. Mattoch, J.B. Robbins, R.L. Kempson, and S. Kohler Post-radiotherapy vascular proliferations in mammary skin: a clinicopathologic study of 11 cases J Am Acad Dermatol 57 2007 126 133
4. T. Brenn, and C.D. Fletcher Radiation-associated cutaneous atypical vascular lesions and angiosarcoma: clinicopathologic analysis of 42 cases Am J Surg Pathol 29 2005 983 996
5. P. Rouhani, C.D. Fletcher, S.S. Devesa, and J.R. Toro Cutaneous soft tissue sarcoma incidence patterns in the U.S.: an analysis of 12,114 cases Cancer 113 2008 616 627
6. J. Weaver, and S.D. Billings Postradiation cutaneous vascular tumors of the breast: a review Semin Diagn Pathol 26 2009 141 149
7. T. Mentzel, H.U. Schildhaus, G. Palmedo, R. Buttner, and H. Kutzner Postradiation cutaneous angiosarcoma after treatment of breast carcinoma is characterized by MYC amplification in contrast to atypical vascular lesions after radiotherapy and control cases: clinicopathological, immunohistochemical and molecular analysis of 66 cases Mod Pathol 25 2012 75 85
8. C. Gengler, J.M. Coindre, A. Leroux, and et al. Vascular proliferations of the skin after radiation therapy for breast cancer: clinicopathologic analysis of a series in favor of a benign process: a study from the French Sarcoma Group Cancer 109 2007 1584 1598
9. J. Manner, B. Radlwimmer, P. Hohenberger, and et al. MYC high level gene amplification is a distinctive feature of angiosarcomas after irradiation or chronic lymphedema Am J Pathol 176 2010 34 39
10. A.P. Fernandez, Y. Sun, R.R. Tubbs, J.R. Goldblum, and S.D. Billings FISH for MYC amplification and anti-MYC immunohistochemistry: useful diagnostic tools in the assessment of secondary angiosarcoma and atypical vascular proliferations J Cutan Pathol 39 2012 234 242
11. J.S. Ko, S.D. Billings, C.P. Lanigan, D. Buehler, A.P. Fernandez, and R.R. Tubbs Fully automated dual-color dual-hapten silver in situ hybridization staining for MYC amplification: a diagnostic tool for discriminating secondary angiosarcoma J Cutan Pathol 41 2014 286 292
12. P.S. Ginter, J.M. Mosquera, T.Y. MacDonald, T.M. D'Alfonso, M.A. Rubin, and S.J. Shin Diagnostic utility of MYC amplification and anti-MYC immunohistochemistry in atypical vascular lesions, primary or radiation-induced mammary angiosarcomas, and primary angiosarcomas of other sites Hum Pathol 45 2014 709 716
13. A. Italiano, R. Thomas, M. Breen, and et al. The miR-17-92 cluster and its target THBS1 are differentially expressed in angiosarcomas dependent on MYC amplification Genes Chromosomes Cancer 51 2012 569 578
14. W. Shon, W.R. Sukov, S.M. Jenkins, and A.L. Folpe MYC amplification and overexpression in primary cutaneous angiosarcoma: a fluorescence in-situ hybridization and immunohistochemical study Mod Pathol 27 2014 509 515
15. T. Guo, L. Zhang, N.E. Chang, S. Singer, R.G. Maki, and C.R. Antonescu Consistent MYC and FLT4 gene amplification in radiation-induced angiosarcoma but not in other radiation-associated atypical vascular lesions Genes Chromosomes Cancer 50 2011 25 33
16. O. Aprelikova, K. Pajusola, J. Partanen, and et al. FLT4, a novel class III receptor tyrosine kinase in chromosome 5q33-qter Cancer Res 52 1992 746 748
17. F. Galland, A. Karamysheva, M.G. Mattei, O. Rosnet, S. Marchetto, and D. Birnbaum Chromosomal localization of FLT4, a novel receptor-type tyrosine kinase gene Genomics 13 1992 475 478
18. F. Galland, A. Karamysheva, M.J. Pebusque, and et al. The FLT4 gene encodes a transmembrane tyrosine kinase related to the vascular endothelial growth factor receptor Oncogene 8 1993 1233 1240
19. T.A. Partanen, K. Alitalo, and M. Miettinen Lack of lymphatic vascular specificity of vascular endothelial growth factor receptor 3 in 185 vascular tumors Cancer 86 1999 2406 2412
20. L.A. Sullivan, and R.A. Brekken The VEGF family in cancer and antibody-based strategies for their inhibition MAbs 2 2010 165 175
21. S. Pelengaris, M. Khan, and G. Evan c-MYC: more than just a matter of life and death Nat Rev Cancer 2 2002 764 776
22. C.V. Dang c-Myc target genes involved in cell growth, apoptosis, and metabolism Mol Cell Biol 19 1999 1 11
23. T.A. Baudino, C. McKay, H. Pendeville-Samain, and et al. c-Myc is essential for vasculogenesis and angiogenesis during development and tumor progression Genes Dev 16 2002 2530 2543
24. C.C. Pan, J.C. Bloodworth, K. Mythreye, and N.Y. Lee Endoglin inhibits ERK-induced c-Myc and cyclin D1 expression to impede endothelial cell proliferation Biochem Biophys Res Commun 424 2012 620 623
25. J.K. Feller, and M. Mahalingam c-myc and cutaneous vascular neoplasms Am J Dermatopathol 35 2013 364 369
26. K.T. Patton, A.T. Deyrup, and S.W. Weiss Atypical vascular lesions after surgery and radiation of the breast: a clinicopathologic study of 32 cases analyzing histologic heterogeneity and association with angiosarcoma Am J Surg Pathol 32 2008 943 950
27. A.L. Folpe, T. Veikkola, R. Valtola, and S.W. Weiss Vascular endothelial growth factor receptor-3 (VEGFR-3): a marker of vascular tumors with presumed lymphatic differentiation, including Kaposi's sarcoma, kaposiform and Dabska-type hemangioendotheliomas, and a subset of angiosarcomas Mod Pathol 13 2000 180 185
28. C.C. Mankey, J.B. McHugh, D.G. Thomas, and D.R. Lucas Can lymphangiosarcoma be resurrected? A clinicopathological and immunohistochemical study of lymphatic differentiation in 49 angiosarcomas Histopathology 56 2010 364 371
29. B.A. Teicher Searching for molecular targets in sarcoma Biochem Pharmacol 84 2012 1 10
30. E. Styring, J. Seinen, M. Dominguez-Valentin, and et al. Key roles for MYC, KIT and RET signaling in secondary angiosarcomas Br J Cancer 111 2014 407 412
31. G. Ranieri, M. Mammi, E. Donato Di Paola, and et al. Pazopanib a tyrosine kinase inhibitor with strong anti-angiogenetic activity: a new treatment for metastatic soft tissue sarcoma Crit Rev Oncol Hematol 89 2014 322 329
32. P. Schoffski, J. Cornillie, A. Wozniak, H. Li, and D. Hompes Soft tissue sarcoma: an update on systemic treatment options for patients with advanced disease Oncol Res Treat 37 2014 355 362